Jian Qiang Li
Fondateur chez Hebei Senlangbio Biotechnology Co., Ltd.
Profil
Jian Qiang Li is the founder and holds the title of Director & Chief Scientific Officer at Hebei Senlangbio Biotechnology Co., Ltd., which was founded in 2016.
Dr. Li obtained a doctorate degree from Julius-Maximilians-Universität Würzburg in 2009 and a graduate degree from Peking Union Medical College in 2006.
Postes actifs de Jian Qiang Li
| Sociétés | Poste | Début |
|---|---|---|
Hebei Senlangbio Biotechnology Co., Ltd.
 Hebei Senlangbio Biotechnology Co., Ltd. BiotechnologyHealth Technology Hebei Senlangbio Biotechnology Co., Ltd. is a clinical-stage biotechnology company based in Shijiazhuang, China. The Chinese company is dedicated to utilizing cell and gene engineering technologies to generate innovative and transformative cellular immunotherapies for solid and hematologic cancers. Senlangbio has three cell therapy technology platforms, including chimeric antigen receptor (CAR) T-cells (CAR-T), allogeneic CAR gamma delta T-cells (CAR-GDT), and armored tumor infiltrating lymphocytes (armTILs). Senlangbio is currently the largest cell therapy company in terms of the scale of bio-manufacturing, as well as the breadth and depth of active pre-clinical research and clinical development programs. The private company is in the process of further capturing the cell therapy markets in other regions and planning for international multi-center clinical studies. The company was founded in 2016 by Jian Qiang Li. | Fondateur | 28/01/2016 |
Formation de Jian Qiang Li
| Julius-Maximilians-Universität Würzburg | Doctorate Degree |
| Peking Union Medical College | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Hebei Senlangbio Biotechnology Co., Ltd.
Hebei Senlangbio Biotechnology Co., Ltd. BiotechnologyHealth Technology Hebei Senlangbio Biotechnology Co., Ltd. is a clinical-stage biotechnology company based in Shijiazhuang, China. The Chinese company is dedicated to utilizing cell and gene engineering technologies to generate innovative and transformative cellular immunotherapies for solid and hematologic cancers. Senlangbio has three cell therapy technology platforms, including chimeric antigen receptor (CAR) T-cells (CAR-T), allogeneic CAR gamma delta T-cells (CAR-GDT), and armored tumor infiltrating lymphocytes (armTILs). Senlangbio is currently the largest cell therapy company in terms of the scale of bio-manufacturing, as well as the breadth and depth of active pre-clinical research and clinical development programs. The private company is in the process of further capturing the cell therapy markets in other regions and planning for international multi-center clinical studies. The company was founded in 2016 by Jian Qiang Li. | Health Technology |
